Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX).

Full DD Report for BCRX

You must become a subscriber to view this report.


Recent News from (NASDAQ: BCRX)

Breakfast Technical Briefing on BioLine Rx and Three More Biotech Stocks
Stock Research Monitor: PETX, BCRX, and BDSI LONDON, UK / ACCESSWIRE / May 17, 2018/ If you want a free Stock Review on BLRX sign up now at www.wallstequities.com/registration . In today's pre-market research, WallStEquities.com evaluates Aratana Therapeutics Inc. (NASDAQ: PETX ), Bi...
Source: ACCESSWIRE IA
Date: May, 17 2018 09:00
Blog Exposure - Proteon Extended Long-term Contract with Lonza for Commercial Supply of Vonapanitase's Active Pharmaceutical Ingredient
Stock Monitor: BioCryst Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / May 10, 2018 / If you want access to our free research report on Proteon Therapeutics, Inc. (NASDAQ: PRTO ), all you need to do is sign up now by clicking the following link www.active-investors.com/reg...
Source: ACCESSWIRE IA
Date: May, 10 2018 07:05
Institutional Top Ideas Series: Ra Capital Management
In the last entry of this series we took a look at top ideas from Orbimed Advisors, a large fund in the midst of a leadership transition which avoids outsized bets (over 5% weighting) yet still has posted decent returns. Going forward, I hope to continue to delve into the portfolios of su...
Source: SeekingAlpha
Date: May, 10 2018 02:04
BioCryst Pharmaceuticals' (BCRX) CEO Jon Stonehouse on Q1 2018 Results - Earnings Call Transcript
BioCryst Pharmaceuticals, Inc. (BCRX) Q1 2018 Earnings Conference Call May 8, 2018 11:00 AM ET Executives Jon Stonehouse - Chief Executive Officer Tom Staab - Chief Financial Officer Bill Sheridan - Chief Medical Officer Analysts Brian Abrahams - Capital Markets Liisa Bay...
Source: SeekingAlpha
Date: May, 08 2018 15:37
BioCryst Pharmaceuticals, Inc. 2018 Q1 - Results - Earnings Call Slides
The following slide deck was published by BioCryst Pharmaceuticals, Inc. in conjunction with their 2018 Q1 earnings Read more ...
Source: SeekingAlpha
Date: May, 08 2018 11:14
BioCryst Pharmaceuticals misses by $0.07, misses on revenue
BioCryst Pharmaceuticals (NASDAQ: BCRX ): Q1 EPS of -$0.26 misses by $0.07 . More news on: BioCryst Pharmaceuticals, Inc., Earnings news and commentary, Stocks on the move, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: May, 08 2018 06:01
BioCryst Reports First Quarter 2018 Financial Results
RESEARCH TRIANGLE PARK, N.C., May 08, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today financial results for the first quarter ended March 31, 2018. “We are off to a strong start in 2018 as we continue to make progress advancing all our HAE d...
Source: GlobeNewswire
Date: May, 08 2018 06:00
Week 19 Breakout Forecast: Short-Term Picks To Give You An Edge
Breakout Forecast Selections for Week 19: Market conditions continue with high volatility. The positive momentum gauge spent another full week in yellow (medium) moving from a value of 52 last week up to a value of 61 this week. The all time low for the positive momentum selection gauge...
Source: SeekingAlpha
Date: May, 06 2018 01:42
BioCryst Receives European Medicines Agency Approval for ALPIVAB(TM) for the Treatment of Influenza
RESEARCH TRIANGLE PARK, N.C., May 01, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), a pharmaceutical company focused on the development and commercialization of treatments for rare diseases, today announced that the European Medicines Agency (EMA) has approved per...
Source: GlobeNewswire
Date: May, 01 2018 06:00
New Research: Key Drivers of Growth for OFG, Oshkosh, Vishay Precision Group, Endocyte, BioCryst Pharmaceuticals, and Trevena - Factors of Influence, Major Initiatives and Sustained Production
NEW YORK, April 26, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of OFG Bancorp (NYSE:OFG), Oshkosh Corporation (NYSE:OSK), Vishay Precision...
Source: GlobeNewswire
Date: April, 26 2018 08:20

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-08-177.047.117.256.9449459,930
2018-08-166.917.027.066.68323,834
2018-08-156.996.877.136.75331,848
2018-08-147.137.007.266.955512,662
2018-08-137.437.177.497.11688,231

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-1757,55494,76460.7340Short
2018-08-1656,477114,61349.2763Short
2018-08-1539,03385,09745.8688Short
2018-08-1450,933119,30942.6900Short
2018-08-1355,289172,06232.1332Cover

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on BCRX.


About BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX)

Logo for BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX)

Not available

 

Contact Information

 

 

Current Management

  • Charles E. Bugg / President, CEO
  • John A. Montgomery / Secretary

Current Share Structure

  • Market Cap: $592,622,721 - 05/14/2018
  • Issue and Outstanding: 98,606,110 - 01/31/2018

 


Recent Filings from (NASDAQ: BCRX)

Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: May, 10 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: May, 10 2018
Filing of certain prospectuses and communications in connection with business combination transactions
Filing Type: 425Filing Source: edgar
Filing Date: May, 09 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 09 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 08 2018
Filing of certain prospectuses and communications in connection with business combination transactions
Filing Type: 425Filing Source: edgar
Filing Date: May, 08 2018
Filing of certain prospectuses and communications in connection with business combination transactions
Filing Type: 425Filing Source: edgar
Filing Date: May, 08 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 01 2018
Filing of certain prospectuses and communications in connection with business combination transactions
Filing Type: 425Filing Source: edgar
Filing Date: April, 10 2018
Filing of certain prospectuses and communications in connection with business combination transactions
Filing Type: 425Filing Source: edgar
Filing Date: April, 10 2018

 

 


Daily Technical Chart for (NASDAQ: BCRX)

Daily Technical Chart for (NASDAQ: BCRX)


Stay tuned for daily updates and more on (NASDAQ: BCRX)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: BCRX)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in BCRX is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of BCRX and does not buy, sell, or trade any shares of BCRX. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/